Welcome to our dedicated page for Telefonica news (Ticker: VIV), a resource for investors and traders seeking the latest updates and insights on Telefonica stock.
Telefônica Brasil reports developments for its Vivo telecommunications business in Brazil, including mobile postpaid service, fiber-to-the-home broadband, fixed revenues, corporate data, ICT and digital services, and 5G network investment. Company updates commonly cover revenue, EBITDA, net income, operating cash flow, ARPU, churn, customer access trends, homes passed and connected, and capital spending across mobile and fiber operations.
News for VIV also includes shareholder remuneration actions such as interest on capital, capital reductions and share buyback programs, along with annual Form 20-F filing announcements and governance-related disclosures for its NYSE-listed American depositary shares and B3-listed common shares.
Telefônica Brasil (B3: VIVT3; NYSE: VIV) reported a historic net revenue growth of 4.6% YoY in 1Q22, reaching R$ 11,352 million, marking its highest growth in seven years. The company achieved a total of 100 million accesses, with 91.9% being core subscribers. Mobile service revenue rose by 5.7%, bolstered by 1.3 million new postpaid customers. However, total costs increased by 7.0%, outpacing inflation at 11.3%. EBITDA was R$ 4,511 million, with a margin of 39.7%. The acquisition of Oi’s mobile assets could yield R$ 5.4 billion in synergies.
Telefônica Brasil (NYSE: VIV) reported a net income of R$6.2 billion for 4Q21, marking a significant 30.6% increase from 2020. The company achieved net operating revenues of R$11.5 billion, a 2.8% rise year-on-year. Mobile revenues grew by 3.7%, with postpaid customers reaching 49.6 million. Total costs rose 4% but remained below inflation. The recurring EBITDA was R$4.933 billion, yielding a margin of 42.9%. Free cash flow stood at R$7.4 billion, and dividends of R$6.3 billion were distributed, translating to a 7.7% yield.
Telefônica Brasil (B3: VIVT3; NYSE: VIV) reported strong financial results for 3Q21, with net operating revenues reaching R$11,033 million, a 2.2% increase year-on-year. Mobile service revenue experienced its best annual growth in six years, up 5.7%, leading to a net profit surge of 8.5% to R$1,315 million.
Recurring EBITDA also grew by 2.1% to R$4,414 million, maintaining a steady margin of 40.0%. The company declared R$1.9 billion in interest on capital, realizing a dividend yield of 7.4%, while free cash flow amounted to R$2,634 million.
Telefônica Brasil (B3: VIVT3; NYSE: VIV) reported a strong performance in 2Q21, with net income increasing by 20.9% year-over-year to R$1,345 million. The company experienced revenue growth driven by mobile and fiber accesses, with net operating revenues reaching R$10,649 million (+3.2% y-o-y). Core revenue rose to R$9,453 million (+8.2% y-o-y), while fiber revenues surged 49.7%. Despite total costs rising by 3.4%, recurring EBITDA climbed 3.0% to R$4,226 million. The company maintained a dividend yield of 7.7%, showcasing efficient financial management.
Telefônica Brasil (B3: VIVT3; NYSE: VIV) reported a positive 1Q21, with net revenues increasing by 0.2% year-on-year to R$10,849 million, driven by growth in fiber and core businesses. Key metrics include a 4.7% increase in core revenue to R$9,563 million and a significant 17.2% rise in fixed core revenue. EBITDA rose to R$4,455 million (+0.5% y-o-y) with a margin of 41.1%. Free cash flow improved by 3.7% to R$2,199 million. Shareholder remuneration declared reached R$700 million, yielding a 7.9% dividend. The company continues to expand its digital service offerings.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has received approval from the TSX Venture Exchange to extend the expiry date of certain outstanding warrants. Initially set to expire on March 31, 2021, these warrants allow for the purchase of 2,774,991 common shares at $0.90 each, with the new expiry date set for June 1, 2021. All other terms remain unchanged. This approval follows the Corporation's earlier announcement on March 5, 2021, regarding its intention to extend these warrants.
Avivagen Inc. (TSXV:VIV) has approved the issuance of 577,500 stock options to its officers, directors, consultants, and employees. These options will vest over an eight-quarter period and are exercisable within five years at a strike price of $0.56. This issuance forms part of the total remuneration package for these individuals. Additionally, the grants are subject to approval from the TSX Venture Exchange. Avivagen focuses on products for livestock, companion animals, and human health, leveraging its OxC-beta™ technology to promote immune function and improve health economically.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced it will seek approval from the TSX Venture Exchange to extend the expiration date of warrants for 2,774,992 common shares at $0.90 per share, originally set to expire on March 31, 2021, to June 1, 2021. This extension is subject to approval by the exchange and will not alter any other terms of the warrants. Avivagen focuses on developing products that enhance immune function in livestock, companion animals, and humans, utilizing its OxC-beta™ technology as a non-antibiotic alternative in livestock feeds.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced the publication of a study in Poultry Science demonstrating the benefits of its OxC-betaTM Livestock product for broiler poultry. The research highlights significant improvements in growth performance and feed efficiency in birds supplemented with OxC-beta compared to control groups. Conducted in Canada and Scotland, the trials support OxC-beta as a non-antibiotic alternative for enhancing poultry health and performance. CEO Kym Anthony emphasizes the publication's validation of OxC-beta's commercial benefits, appealing to customers aiming to reduce antibiotic use.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announces its Q1 2021 financial results, reporting revenues of $261,987 and a comprehensive loss of $(1,266,300). Major milestones include securing a recurring order of 6 tonnes with Transformadora Agricola in Mexico and fulfilling orders in the Philippines, Taiwan, and Thailand. Subsequent achievements include a $7.5 million oversubscribed financing and expansion into Central and South America with Meyenberg International. The company emphasizes a bright outlook for 2021 with increased order volumes anticipated.